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Abstract Cruzipain, the major cysteine proteinase from Try- 
panosoma cruzi epimastigotes, purified to a sequentially pure 
form, exists in multiple forms with pl values between 3.7 and 5.1, 
and an apparent molecular mass of 41 kDa. The enzyme is stable 
between pH 4.5-9.5. Cruzipain was found to be rapidly and 
tightly inhibited by various protein inhibitors of the cystatin su- 
perfamily (ka. = 1.7-79 × 106 M-Is -1, K d = 1.4-72 pM). These 
results suggest a possible defensive role for the host's cystatins 
after parasite infection, and may be of use for the design of new 
therapeutic drugs. 
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I. Introduction 
Cysteine proteinases comprise a group of enzymes which 
share extensive sequence homology and a common catalytic 
mechanism [1]. They are found in bacteria, protozoa, plants 
and animals. The protozoan parasite Trypanosoma cruzi is the 
causative agent of the American trypanosomiasis, Chagas' dis- 
ease, which affects more than 24 million people in Latin Amer- 
ica. It contains a major cysteine proteinase, cruzipain [2] that 
is a high mannose-type glycoprotein [3] present in the different 
developmental forms of the parasite [4] and is located in the 
lysosomes [5]. The enzyme is an immunodominant antigen, 
recognised in human sera from patients with chronic Chagas 
disease [6]. Cruzipain may be involved in the defense mecha- 
nism of the parasite against he host immune response, both by 
hydrolyzing the Fc moiety of antibodies [7] and by participating 
in the penetration of the trypomastigote into the mammalian 
cell [8]. Recent studies with inhibitors have shown its relevance 
in the differentiation steps of the parasite's life cycle [9]. 
Cruzipain has been purified from epimastigotes of T. cruzi 
and characterized [10-12]. It is inhibited by E-64, a strong 
irreversible inhibitor of cysteine proteinases [11]. Cruzipain is 
composed of two domains: a catalytic domain homologous to 
papain-like proteinases [13] and a domain which represents a 
C-terminal extension to the mature nzyme [14]. This C-termi- 
nal domain can be removed autocatalytically from the catalytic 
domain [15]. 
Cruzipain is encoded by a large number of tandemly ar- 
ranged genes containing repeated units. The genes code for the 
preproenzyme form, complete with C-terminal extension 
[3,16,17]. Very recently, recombinant cruzipain without this 
C-terminal domain (also known as cruzain) was crystallized 
and its structure in complex with Z-Phe-Ala-fluoromethyl 
ketone determined [18]. 
Although the cystatins are well known to be strong compet- 
itive inhibitors of cysteine proteinases [19], there are no data 
available concerning their action on cruzipain. 
In this report we present evidence that cystatins are also very 
potent inhibitors of cruzipain, thus indicating their possible 
defense role in the host organism. They may serve as promising 
starting points for the design of non-covalently bound reversi- 
ble inhibitors as new antiparasite drugs. 
2. Materials and methods 
2.1. Inhibitors 
Human stefin A [20], recombinant human stefin A [21], recombinant 
human stefin B [22], chicken cystatin [23], recombinant human cystatin 
C [24] and human low molecular weight kininogen [25] were purified 
by published procedures. 
The proportion of active inhibitor in each preparation was deter- 
mined by titrations against active-site itrated papain (EC 3.4.22.2,  x 
crystallized, Sigma), monitored by loss of enzyme activity [26], or by 
fluorescence titrations with purified papain [23]. The active concentra- 
tion of kininogen was determined using a 2:1 enzyme to inhibitor 
binding stoichiometry (B. Turk, unpublished results). 
*Corresponding author. Fax: (386) (61) 273 594. 
Abbreviations: -AMC, 4-methyl-7-coumarylamide; EDTA, ethylenedi- 
aminetetraacetic acid; E-64, 1-[L-N-(trans-epoxysuccinyl)leucyl]amino- 
4-guanidino butane; Ep-475, L-trans-epoxysuccinylleucylamido- 
(3-guanidino)butane; FPLC, fast protein liquid chromatography; Mr,
relative molecular weight; PAGE, polyacrylamide g l electrophoresis; 
pI, isoelectric point; SDS, sodium dodecyl sulphate; Z-, benzyloxycar- 
bonyl. 
2.2. Enzyme purification 
Cruzipain was isolated from a cell-free xtract of T. cruzi epimastigo- 
tes as previously described [10]. The material from the Mono Q chrom- 
atography step was dialysed against 0.1 M acetate buffer pH 5.5, con- 
taining 0.3 M NaC1 and 1 mM EDTA, and applied to a Superdex 
75 HR 10130 column (Pharmacia, Sweden) equilibrated with the same 
buffer. The pooled active fractions were concentrated and stored at 
-20°C until used. The active concentration of cruzipain was deter- 
mined by active site titration with Ep-475 [26]. 
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2.3. Analytical methods 
Protein concentration was determined spectrophotometrically at 280 
nm with the use of published [21,23] or calculated absorbance coeffi- 
cients and molecular masses obtained from amino acid sequences [27]. 
SDS-PAGE was performed under non-denaturing conditions on 
8 25% PhastSystem gradient electrophoresis gels (Pharmacia, Sweden). 
Analytical isoelectric focussing was done on PhastSystem Gel IEF 3 9 
slabs (Pharmacia, Sweden), following the manufacturer's in tructions. 
Proteins were stained with Coomassie brilliant blue (Pharmacia, Swe- 
den). 
N-terminal sequence analysis was performed on an Applied Biosys- 
terns 475A liquid-pulse sequencer, connected to a 120A PTH Analyzer 
from the same manufacturer. 
2.4. Enzyme assay 
Cruzipain activity was assayed using 10 gM Z-Phe-Arg-MCA 
(Bachem, Switzerland) in 0.1 M phosphate buffer pH 6.5, containing 
1 mM EDTA and 2 mM ditbiothreitol [28]. 
After 10 rain incubation, the reaction was stopped with iodoacetic 
acid and the fluorescence of the released amidomethylcoumarin meas- 
ured at excitation and emission wavelengths of 370 and 460 nm respec- 
tively; using a Perkin Elmer Luminescence-spectrometer LS 30(USA). 
Measurements to determine the kinetic constants were made using a 
Perkin Elmer Luminescence-spectrometer LS 50 (USA). 
2.5. Determination of pH optimum and pH stability 
These properties were measured in buffers, made from 0.1 M citric 
acid and 0.2 M Na2HPO 4.H20 (pH 3.0-8.0) and 0.05 M Tris/HCl 
(pH 8.0-11.0). 
The activity of cruzipain (0.5 nM final concentration) was assayed 
as described in 2.4 at 0.5 pH unit intervals. 
The pH stability was determined by incubation of 10/ll of enzyme 
and 90/tl of buffers of the given pH for 30 min at 37°C. Activity was 
then assayed at the optimum pH, 6.5. 
2.6. Determination of K,,, 
The initial velocities of hydrolysis of different concentrations of
Z-Phe-Arg-MCA by preactivated cruzipain were measured as in section 
2.4. The substrate was dissolved in 0.1 M phosphate buffer pH 6.5, 
containing 1.5 mM EDTA. K,,~ and Vm,~ values were obtained by non- 
linear regression analysis. 
2. 7. Kinetics and equilibrium of interaction with inhibitors 
Association rate constants and inhibition constants for the reaction 
ofcruzipain with recombinant s efin A and chicken cystatin were meas- 
ured in 0.05 M Tris/HC1 pH 7.4, containing 0.1 M NaC1 and 100/tM 
EDTA, as described [21]. The kinetics of dissociation of the complex 
of cruzipain with chicken cystatin, form 2, were evaluated in the same 
buffer by trapping the enzyme dissociated from the complex with an 
excess of chicken cystatin, form 1 [29]. Association and dissociation rate 
constants for the interaction of cruzipain with stefin A, recombinant 
stefin B, recombinant cystatin C and kininogen were measured in the 
same buffer by methods described previously [26]. The measurements 
of kinetic and equilibrium constants were made by continuous rate 
assays in the presence of 10 ,uM Z-Phe-Arg-AMC, with at least a 
ten-fold molar excess of inhibitor over enzyme. Fluorescence was meas- 
ured as in section 2.4. or in a DX 17MV stopped-flow instrument 
(Applied Photophysics, UK), with excitation at 360 nm and emission 
observed through a cut-off ilter with 50% transmission at400 nm [30]. 
Cruzipain was activated with 1-2 mM dithiothreitol for 5 min before 
each measurement. Less than 5% substrate was hydrolysed in all exper- 
iments. 
3. Results and discussion 
3.1. Enzyme purification and properties 
The cysteine proteinase cruzipain was purified from T. cruzi 
epimastigotes by a published procedure up to the Mono Q 
chromatography step [10], with an additional gel chromatogra- 
phy step on Superdex 75 which separated cruzipain from some 
low molecular mass proteins. After this final step, which im- 
proves on the Superose 12 gel fi ltration previously used [10], the 
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Fig. 1. SDS-PAGE of cruzipain under non-reducing conditions. Lane 
1, cruzipain; Lane 2, protein standards. 
enzyme appeared pure by N-terminal sequence analysis. The 
first 10 amino acid residues corresponded to the published 
N-terminal sequence of cruzipain [16]. The enzyme had an 
apparent molecular mass of 41 kDa, as estimated by gel chrom- 
atography on a calibrated Superdex 75 HR column. Moreover, 
only one band, corresponding to 41 kDa, was visible in SDS- 
PAGE under non-reducing conditions (Fig. 1). The apparent 
molecular mass is compatible with the amino acid sequence of 
cruzipain [16] and the known glycosylation [3]. Under these 
experimental conditions anomalous electrophoretic migration 
giving different apparent molecular masses of the enzyme [31] 
was not observed. 
Cruzipain appeared in multiple forms with pI values between 
3.7 and 5.1 (Fig. 2), probably due to heterogeneity in both 
amino acid sequence and glycosylation in the C-terminal do- 
main (J. Martinez, J. Henriksson, U. Petterson and J.J. 
Cazzulo, unpublished results). 
The enzyme showed optimal activity at pH 6.5 against the 
fluorogenic substrate, Z-Phe-Arg-MCA, and was stable be- 
tween pH 4.5 and 9.5. Cruzipain thus is more stable than lyso- 
Table 1 
Dissociation equilibrium constants (Ka), association rate constants 
(k,~) and dissociation rate constants (kd~ss) for the interaction between 
cruzipain and cysteine proteinase inhibitors 
Inhibitor 1012 × Ka 10 6 x k~ 104 × kdis~ 
(M) (M -I s -t) (s l) 
rstef inA 21.0+0.2(11) 1.7+0.,2(11) 0.36+0.3* 
stefin A 72.0 + 1.2" 3.4 + 0.2 (9) 2.5 _+ 0.3 (9) 
r stefin B 60.0 + 1.0 ° 30.0 + 0.2 (7) 18.0 + 0.2 (7) 
r human cystatin C 14.0 + 0.4 ° 79.0 _+ 0.5 (7) 10.0 + 0.2 (7) 
chicken cystatin 1.4 + 0.2" 73.0 + 0.3 (8) 1.0 + 0.1 (7) 
2.8 + 0.2 (9) 
L-kininogen 41.0_+0.8 " 18.0+0.1 (8) 7.4+0.8 (8) 
The experimental conditions are described in section 2. *Calculated 
from kass and Kd. "Calculated from k,~s and kd~s~. Measured values are 
given with their standard errors and the number of measurements are 
given in parentheses. 
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Fig. 2. Isoelectric lbcusing of pure cruzipain. Lane 1, cruzipain; Lane 
2, protein standards. 
somal cathepsins, which are inactivated under slightly alkaline 
conditions [28,32]. 
3.2. Kinetic measurements 
Kinetic and equilibrium constants were determined for the 
interaction of the cysteine proteinase inhibitors, stefins A and 
B, cystatin C, chicken cystatin and kininogen, with cruzipain 
(Table 1). Association rate constants were measured under 
pseudo-first-order conditions by a continuous fluorimetric 
assay. Typical biphasic progress curves were recorded in all 
experiments. The dependence of the observed pseudo-first- 
order rate constant (kobs) on inhibitor concentration was linear 
for all inhibitors, in agreement with a simple, competitive inhi- 
bition mechanism [29,30]. The association rate constants (ka~) 
were calculated from the slope of the plot of kob ~ vs. inhibitor 
concentration a d were corrected for substrate competition. K~ 
value of 0.27 pM had been obtained. Dissociation rate con- 
stants (ka~) were obtained either from the kinetic experiments, 
as described previously [24], or were measured by a displace- 
ment technique in the case of chicken cystatin [29]. Dissociation 
equilibrium constants, Kd, were then calculated from the asso- 
ciation and dissociation rate constants as K~ = kaiJk~ ~. Alter- 
natively, dissociation equilibrium constants for the interaction 
of cruzipain with stefin A and chicken cystatin were measured 
as inhibition constants, corrected for substrate competition as 
above [21]. The approximate quivalence in binding of cruzi- 
pain to natural and recombinant s efin A is indicated by the 
comparable dissociation constants obtained. The data further 
show that all inhibitors tudied are highly active in inhibiting 
cruzipain. They bind rapidly and tightly to the enzyme with Ka 
values between ~2 and ~70 pM, cystatin C and chicken cystatin 
having somewhat higher affinities than the others. There are 
also some differences in the rates of association of the inhibitors 
with the enzyme, cystatin C and chicken cystatin reacting faster 
than stefin A. 
In conclusion, the results of this study provide clear evidence 
that the cysteine proteinase from T. cruzi can be efficiently 
inhibited by host cystatins. A similar enzyme from Trypano- 
soma congolense, trypanopain, has also been shown to be inhib- 
ited by cystatins [33]. Parasite proteinases are attractive targets 
for drug design due to their key role in the parasite life cycles, 
as proved by the effects of inhibitors on the parasite's growth 
and differentiation, and in the pathogenesis of the diseases in 
host organisms, including humans. This has been shown for 
parasitic protozoa, ranging from Entamoeba histolytica [34], 
Plasmodium fidciparum [35], T. congolence [33] to T. cruzi [9]. 
Therefore, the data presented here may be of significance for 
the design of new compounds as possible therapeutic agents for 
the treatment of Chagas' disease. 
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